A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE)
Loibl S, Schmidt M, Luebbe K, Decker T, Thill M, Bauer L, Mueller V, Link T, Furlanetto J, Kuemmel S, Mundhenke C, Hoffmann O, Zahn MO, Mueller L, Denkert C, Van Mackelenbergh M, Fasching P, Burchardi N, Nekljudova V (2021)
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S1292-S1293
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2021.08.2092
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Essen
Germany (DE)
Universitätsklinikum Gießen und Marburg (UKGM)
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
GRN-Klinik Weinheim
Germany (DE)
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Germany (DE)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Technische Universität Dresden
Germany (DE)
DIAKOVERE gGmbH (Diakonische Dienste Hannover (DDH))
Germany (DE)
Agaplesion Markus Krankenhaus
Germany (DE)
Klinikum Bayreuth
Germany (DE)
Germany (DE)
Universitätsklinikum Gießen und Marburg (UKGM)
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
GRN-Klinik Weinheim
Germany (DE)
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Germany (DE)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Technische Universität Dresden
Germany (DE)
DIAKOVERE gGmbH (Diakonische Dienste Hannover (DDH))
Germany (DE)
Agaplesion Markus Krankenhaus
Germany (DE)
Klinikum Bayreuth
Germany (DE)
How to cite
APA:
Loibl, S., Schmidt, M., Luebbe, K., Decker, T., Thill, M., Bauer, L.,... Nekljudova, V. (2021). A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE). In ANNALS OF ONCOLOGY (pp. S1292-S1293). AMSTERDAM: ELSEVIER.
MLA:
Loibl, S., et al. "A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE)." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2021. S1292-S1293.
BibTeX: Download